Patents Assigned to Surefire Medical, Inc. d/b/a TriSalus Life Sciences
  • COMBINATION INCLUDING A CPG-C TYPE OLIGONUCLEOTIDE AND A PD-1 ANTAGONIST FOR TREATING BREAST CANCER
    Publication number: 20210315991
    Abstract: The present disclosure describes combination therapies for breast cancer comprising an oligonucleotide toll-like receptor 9 agonist and a PD-1 antagonist. In particular, the present disclosure describes combinations of a CpG-C type oligonucleotide and an anti-PD-1 antibody for the treatment of breast cancer. The combination may further comprise a taxane chemotherapeutic agent, in the presence or absence of a corticosteroid.
    Type: Application
    Filed: April 13, 2021
    Publication date: October 14, 2021
    Applicants: Surefire Medical, Inc. d/b/a TriSalus Life Sciences, The Regents of the University of California, H. Lee Moffitt Cancer Center and Research Institute, Inc.
    Inventors: Robert S. Janssen, Erick Gamelin, Laura J. Esserman, Amy Jo Chien, Hetem Soliman